23andMe Investor Presentation Deck

(in $M, except percentages) Consumer Services Research Services Therapeutics Total Revenue Amount $138 33 $171 Revenue Composition Nine Months Ended December 31, FY2022 Percentage of Revenue 81% 19% 100% Amount $119 36 O $155 FY2021 Percentage of Revenue 77% 23% 0% 100% Year Ended March 31, Amount $198 46 O $244 FY2021 Copyright © 2022 23and Me, Inc. Percentage of Revenue 81% 19% 0% 100% 23andMe 53

View entire presentation